Astral shares in focus on demerger news but JPMorgan downgrades; check price targets

Another brokerage firm CLSA said the demerger is unlikely to have a meaningful impact on the stock in the near term, adding that sustained growth and margin improvement in the chemicals business will be the key drivers for any future rerating.

Leave a Reply

Your email address will not be published. Required fields are marked *